Literature DB >> 12100729

Herpes simplex virus 1 infected neuronal and skin cells differ in their susceptibility to complement attack.

Riina Rautemaa1, Tuula Helander, Seppo Meri.   

Abstract

Herpes simplex virus type 1 (HSV-1) infection in neurons is lifelong and generally asymptomatic. Reactivation of this latent infection results in skin blistering whereas the respective peripheral neurons are rarely affected. Why the neuronal cells are spared while the skin cells are sacrificed is not well understood. In the present study our aim was to study whether neuronal and skin cells differ in their ability to control complement attack during HSV-1 infection. Human embryonal skin (HES) cells and neuronal Paju cells were infected by HSV-1 in vitro. Both types of infected cells activated complement but were initially resistant to membrane attack complex (MAC) deposition. During the first hours of infection the expression of the endogenous complement regulators decay accelerating factor (DAF) and CD59 increased on both HES and Paju cells. By 12 hr the infected HES cells had lost their ability to control complement attack. The expression of DAF and CD59 decreased and the cells became targets for MAC attack. In contrast, complement regulator expression on the Paju cells did not decrease below the initial level and complement C5b-9 deposition was found only on 10% of the Paju cells at 12 hr. The results suggest that HSV-infected neuronal cells are better than skin cells in protecting themselves against complement attack. This may contribute to the persistence of a latent HSV-1 infection in neuronal cells for prolonged periods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100729      PMCID: PMC1782739          DOI: 10.1046/j.1365-2567.2002.01421.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

Review 1.  Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry.

Authors:  R Würzner
Journal:  Mol Immunol       Date:  1999 Mar-Apr       Impact factor: 4.407

Review 2.  Complement-resistance mechanisms of bacteria.

Authors:  R Rautemaa; S Meri
Journal:  Microbes Infect       Date:  1999-08       Impact factor: 2.700

Review 3.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 4.  Three classes of cell surface receptors for alphaherpesvirus entry.

Authors:  P G Spear; R J Eisenberg; G H Cohen
Journal:  Virology       Date:  2000-09-15       Impact factor: 3.616

5.  Subclinical reactivation of herpes simplex virus type 1 in the oral cavity.

Authors:  B Knaup; S Schünemann; M H Wolff
Journal:  Oral Microbiol Immunol       Date:  2000-10

6.  Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells.

Authors:  K Z Zhang; S Junnikkala; M G Erlander; H Guo; J A Westberg; S Meri; L C Andersson
Journal:  Eur J Immunol       Date:  1998-04       Impact factor: 5.532

7.  Humoral response to herpes simplex virus is complement-dependent.

Authors:  X J Da Costa; M A Brockman; E Alicot; M Ma; M B Fischer; X Zhou; D M Knipe; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

8.  Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.

Authors:  H M Friedman; L Wang; N O Fishman; J D Lambris; R J Eisenberg; G H Cohen; J Lubinski
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.

Authors:  H M Friedman; L Wang; M K Pangburn; J D Lambris; J Lubinski
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

10.  In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.

Authors:  J Lubinski; L Wang; D Mastellos; A Sahu; J D Lambris; H M Friedman
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  7 in total

Review 1.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

2.  Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.

Authors:  Tohti Amet; Jie Lan; Nicole Shepherd; Kai Yang; Daniel Byrd; Yanyan Xing; Qigui Yu
Journal:  AIDS Res Hum Retroviruses       Date:  2016-07-27       Impact factor: 2.205

3.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

Review 4.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

5.  Seroprevalence of Cytomegalo Virus (CMV) among pregnant women in Thika, Kenya.

Authors:  Zakayo Maingi; Anthony Kebira Nyamache
Journal:  BMC Res Notes       Date:  2014-11-12

6.  HSV-Encephalitis Reactivation after Cervical Spine Surgery.

Authors:  Joshua E Heller; Geoffrey Stricsek; Lauren Thaete
Journal:  Case Rep Surg       Date:  2019-04-10

7.  Complement and CD4+ T cells drive context-specific corneal sensory neuropathy.

Authors:  Derek J Royer; Jose Echegaray-Mendez; Liwen Lin; Grzegorz B Gmyrek; Rose Mathew; Daniel R Saban; Victor L Perez; Daniel Jj Carr
Journal:  Elife       Date:  2019-08-15       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.